Loading stock data…
CONMED Corporation (CNMD)
$34.41-1.54 (-4.28%)
After Hours$34.41+0.00 (+0.00%)· Last close Jun 29
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CONMED Corporation in the Healthcare sector is trading at $34.41 with a market capitalization of $1.1B. Wall Street consensus targets $39.60 (5 analysts), implying a +15.1% move over the next 12 months. The stock is currently near its 52-week low of $31.44, remaining 15.7% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +15.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $317.05M↓ | $373.20M↑ | $337.93M↓ | $342.35M↑ | $321.26M |
| Gross Profit | $183.45M↓ | $218.28M↑ | $166.12M↓ | $188.32M↑ | $177.75M |
| Operating Income | $25.41M↓ | $36.62M↑ | $11.88M↓ | $38.16M↑ | $15.96M |
| Net Income | $13.83M↓ | $16.74M↑ | $2.86M↓ | $21.42M↑ | $6.04M |
Peer Comparison
JNJUNHPFE
Fundamentals
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.16%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.39%
Volume
Today's trading volume
584,748
Recent News
CONMED Lagging Medtech Peers as Growth Slows, BofA Securities Says
CONMED (CNMD) is likely to trail other medtech stocks over the next year as slower growth, stronger
Will CONMED’s New CFO Shift CNMD’s Financial Playbook Or Deepen Its Existing Strategy?
On June 17, 2026, CONMED Corporation announced that John E. Gallagher will become Executive Vice President, Chief Financial Officer, and principal financial and accounting officer from July 15, 2026, succeeding Todd Garner, who will remain in an advisory role until November 2, 2026. Gallagher’s nearly three decades of finance leadership across healthcare and industrial companies, including senior roles at Certara, Cue Health, and Becton Dickinson, signals a refreshed approach to CONMED’s...
3 Small-Cap Stocks with Questionable Fundamentals
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Q1 Earnings Outperformers: CONMED (NYSE:CNMD) And The Rest Of The Surgical Equipment & Consumables - Diversified Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the surgical equipment & consumables - diversified stocks, including CONMED (NYSE:CNMD) and its peers.
CONMED Board Refresh And Governance Changes Feed Into Valuation Debate
CONMED Corporation (NYSE:CNMD) has added Celine Martin and Jeff Mirviss to its Board of Directors, both with long experience at large medical technology companies. The company has also updated its corporate by laws, adjusting certain governance provisions. In parallel, CONMED has named an Interim Corporate Controller, giving investors fresh information on the finance leadership structure. CONMED focuses on surgical and patient monitoring technologies, a space where product pipelines,...